MetLife Investment Management’s Aimmune Therapeutics AIMT Stock Holding History

MetLife Investment Management’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-20,346	Closed	-$701K	–	2347
2020 Q3	$701K	Hold	20,346	–	–	0.01%	1206
2020 Q2	$340K	Hold	20,346	–	–	﹤0.01%	1592
2020 Q1	$293K	Hold	20,346	–	–	﹤0.01%	1486
2019 Q4	$681K	Hold	20,346	–	–	0.01%	1291
2019 Q3	$426K	Hold	20,346	–	–	﹤0.01%	1510
2019 Q2	$424K	Hold	20,346	–	–	﹤0.01%	1582
2019 Q1	$455K	Hold	20,346	–	–	﹤0.01%	1509
2018 Q4	$487K	Hold	20,346	–	–	0.01%	1385
2018 Q3	$555K	Hold	20,346	–	–	0.01%	1471
2018 Q2	$547K	Buy	20,346 +3,261	+19%	+$99.8K	0.01%	1361
2018 Q1	$544K	Hold	17,085	–	–	0.01%	1324
2017 Q4	$646K	Buy	+17,085	New	+$551K	0.01%	1253

MetLife Investment Management's AIMT Position: Q4 2020 in Review

MetLife Investment Management sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 20,346 shares — an estimated $701K sold.

MetLife Investment Management first reported a position in AIMT in Q4 2017 and held it in 12 quarters. The position peaked at $701K in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

MetLife Investment Management reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
MetLife Investment Management sold 20,346 Aimmune Therapeutics shares in Q4 2020, an estimated $701K.
MetLife Investment Management first reported a position in Aimmune Therapeutics in Q4 2017 and held it in 12 quarters.
MetLife Investment Management's Aimmune Therapeutics position peaked at $701K in Q3 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on MetLife Investment Management's 13F filing for Q4 2020, filed 16 Feb 2021.